Methoxyamine Hydrochloride is a small molecule commercialized by TRACON Pharmaceuticals, with a leading Phase II program in Lymphoma. According to Globaldata, it is involved in 9 clinical trials, of which 5 were completed, 2 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Methoxyamine Hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Methoxyamine Hydrochloride is expected to reach an annual total of $30 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Methoxyamine Hydrochloride Overview
TRC-102 (methoxyamine hydrochloride) is under development for the treatment of advanced or metastatic solid tumors, lung cancer, glioblastoma multiforme (GBM), lymphoma, ovarian cancer, colorectal cancer, mesothelioma. It is administered through oral and intravenous route. It is an inhibitor of base-excision repair intended to reverse resistance to alkylator and antimetabolite chemotherapy. It was under development for the treatment of relapsed or refractory hematologic malignancies, multiple myeloma,chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia, Hodgkin Lymphoma, diffuse large B-Cell lymphoma, nodal T-Cell Lymphomas, mantle cell lymphoma, anaplastic large cell lymphoma and follicular lymphoma, thymoma (thymic epithelial tumor).
TRACON Pharmaceuticals Overview
TRACON Pharmaceuticals (TRACON) is a biopharmaceutical company. It develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC102 is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC102 is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. It also offers products for the treatment of prostate cancer, and hematologic malignancies such as myeloma. The company works in collaboration with universities and medical institutions. TRACON is headquartered in San Diego, California, the US.
For a complete picture of Methoxyamine Hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
